Identification
- Summary
Dermatophagoides pteronyssinus is an extract from Dermatophagoides pteronyssinus used in allergy testing.
- Brand Names
- Acarizax, Odactra
- Generic Name
- Dermatophagoides pteronyssinus
- DrugBank Accession Number
- DB10401
- Background
Dermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Allergenics
Allergen Extract - Synonyms
- AE-mite, dermatophagoides pteronyssinus
- Dermatophagoides pteronyssinus whole
- European house dust mite
- European house dust mite extract
- House dust mite extract, dermatophagoides pteronyssinus
- Insects (whole body), mite dermatophagoides pteronyssinus
- Mite D.P.
- Mite D.P. (dermatophagoides pteronyssinus) standardized
Pharmacology
- Indication
Dermatophagoides pteronyssinus is indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites, or skin testing to licensed house dust mite allergen extracts. It is approved for use in patients 12 through 65 years of age.3
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to manage Allergic rhinitis due to house dust mite Combination Product in combination with: Dermatophagoides farinae (DB10400) •••••••••••• ••••••••••••••• ••••• •••• •••• ••••••• •••••• Used in combination to manage Allergic rhinitis due to house dust mite Combination Product in combination with: Dermatophagoides farinae (DB10400) •••••••••••• ••••• •••• •••• ••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Treatment with ACTAIR has been shown to induce a systemic antibody response towards house dust mite allergens, with an increase in specific IgG4 antibodies in some patients. These immunoglobulins may compete with IgE for allergen binding, thereby decreasing allergen capture and presentation.
- Mechanism of action
The complete mechanisms of allergen immunotherapy are not clear and remain the subject of investigation. The allergic reaction is dependent on the presence of allergen-specific immunoglobulin E (IgE) antibodies that are bound to specific receptors on mast cells and basophils. The presence of IgE antibodies sensitizes these cells, and upon interaction with the appropriate allergens, histamine and other mediators are released which produce local or systemic responses in sensitive individuals, and characteristic symptoms of atopic diseases, such as allergic rhinitis and allergic asthma. Changes in serum antibody and T-lymphocyte responses resulting from immunotherapy have been demonstrated, and these changes often correlate closely with clinical (symptom) improvements. Specific mechanisms may vary depending on the nature of the allergic disease, the allergenic specificities of patients and populations, extract formulations, route of administration, dose and duration of treatment. Subcutaneous administration of allergenic extracts is known to elicit numerous immunological changes that are both time and dose-dependent. Many of these changes appear to be related to (or a precursor to) improvements in symptoms and other clinical parameters, as noted above. Specific changes found after immunotherapy with dust mite extracts include significant increases in mite-specific IgG4 antibodies, interleukin-10-positive T cells, and several T-cell receptors, and significant decreases in serum nitric oxide, eosinophil catonic protein, interleukin-4-positive T cells and IgE-mediated basophil histamine release.
- Absorption
Allergens in ACTAIR consist mainly of proteins and glycoproteins. There is no direct bioavailability of intact allergens in the blood. Therefore, no pharmacokinetic studies in animals or in humans have been carried out to investigate the pharmacokinetic profile and metabolism of ACTAIR.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Allergen Pack Dermatophagoides Pteronyssinus Solution 10000 [AU]/1mL Intradermal; Subcutaneous Alvix Laboratories 2015-06-25 2018-03-08 US 
Allergenic Extract - Standardized Mite Dermatophagoides Pteronyssinus Liquid 5000 unit / mL Intradermal; Subcutaneous Greer Laboratories Not applicable Not applicable Canada 
Allergenic Extract - Standardized Mite Dermatophagoides Pteronyssinus Liquid 10000 unit / mL Intradermal; Subcutaneous Greer Laboratories 1999-03-15 Not applicable Canada Allergenic Extract Standardized Mite Dp Liquid 10000 unit / mL Subcutaneous Hollister Stier, Unit Pharm, Division Of Miles Canada Inc. 1992-12-31 1998-09-25 Canada Allergenic Extract Standardized Mite Dp Liquid 30000 unit / mL Subcutaneous Hollister Stier, Unit Pharm, Division Of Miles Canada Inc. 1992-12-31 1998-09-25 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ACARIZAX Dermatophagoides pteronyssinus (6 AU) + Dermatophagoides farinae (6 AU) Powder Oral บริษัท แอ๊บบอต ลาบอแรตอรีส จำกัด 2018-03-28 Not applicable Thailand 
Acarizax Dermatophagoides pteronyssinus (6 unit) + Dermatophagoides farinae (6 unit) Tablet Sublingual Alk Abelló A/S 2017-11-06 Not applicable Canada ACARIZAX 12 SQ-HDM Lyophilisat zur sublingualen Anwendung Dermatophagoides pteronyssinus (12 SQ-HDM) + Dermatophagoides farinae (12 SQ-HDM) Powder Oral Alk Abelló A/S 2015-11-26 Not applicable Austria 
Allergenic Extract - Standardized Mite Mix Dermatophagoides pteronyssinus (5000 unit / mL) + Dermatophagoides farinae (5000 unit / mL) Liquid Intradermal; Subcutaneous Greer Laboratories 2002-08-20 Not applicable Canada Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml) Dermatophagoides pteronyssinus (15000 unit / mL) + Dermatophagoides farinae (15000 unit / mL) Solution Percutaneous; Subcutaneous Jubilant Hollisterstier Llc 1998-01-16 Not applicable Canada
Categories
- ATC Codes
- V01AA03 — House dust mites
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 57L1Z5378K
- CAS number
- Not Available
References
- General References
- External Links
- PubChem Substance
- 347910576
- 1116979
- Wikipedia
- House_dust_mite
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Allergic Asthma Due to Dermatophagoides Pteronyssinus 1 4 Completed Treatment Allergic Reaction 1 3 Active Not Recruiting Treatment Allergic Rhinitis Due to Dermatophagoides Farinae / Allergic Rhinitis Due to Dermatophagoides Pteronyssinus / House Dust Mite Allergy 1 3 Completed Treatment Allergic Asthma Due to Dermatophagoides Farinae / Allergic Asthma Due to Dermatophagoides Pteronyssinus / House Dust Mite Allergy 1 3 Completed Treatment Allergic Rhinitis (AR) / Rhinoconjunctivitis, Allergic 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Oral Tablet, orally disintegrating Oral Solution Intradermal; Subcutaneous 10000 [AU]/1mL Liquid Intradermal; Subcutaneous 5000 unit / mL Solution Percutaneous; Subcutaneous Injection, solution 10000 AU/1ml Liquid Subcutaneous 10000 unit / mL Liquid Subcutaneous 30000 unit / mL Solution Percutaneous; Subcutaneous 10000 unit / mL Solution Percutaneous; Subcutaneous 30000 unit / mL Liquid Subcutaneous Liquid Intradermal; Percutaneous; Subcutaneous Liquid Intradermal; Percutaneous; Subcutaneous 10000 unit / mL Liquid Intradermal; Subcutaneous 30000 unit / mL Injection, suspension Subcutaneous Injection Cutaneous; Intradermal; Subcutaneous 10000 [AU]/1mL Tablet Sublingual Tablet Sublingual Injection, solution Percutaneous; Subcutaneous 10000 [AU]/1mL Injection, solution Subcutaneous 5000 [AU]/1mL Solution Percutaneous 10000 [AU]/1mL Concentrate Intradermal; Percutaneous; Subcutaneous 10000 [AU]/1mL Concentrate Intradermal; Percutaneous; Subcutaneous 30000 [AU]/1mL Concentrate Intradermal; Percutaneous; Subcutaneous 5000 [AU]/1mL Injection, solution Intradermal; Subcutaneous 10000 [AU]/1mL Concentrate Intradermal; Percutaneous; Subcutaneous Injection, solution Subcutaneous Liquid Intradermal; Subcutaneous 10000 unit / mL Injection, solution Intradermal; Subcutaneous 3000 [AU]/1mL Injection, solution Intradermal; Subcutaneous 5000 [AU]/1mL Injection, solution Subcutaneous 10000 [AU]/1mL Injection, solution Intradermal 30 [AU]/1mL Injection, solution Intradermal 300 [AU]/1mL Injection, solution Percutaneous; Subcutaneous 30000 [AU]/1mL Liquid Intradermal; Subcutaneous Injection, solution Percutaneous Injection, solution Intradermal; Subcutaneous Solution 10000 AU/1ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at December 01, 2015 20:03 / Updated at April 23, 2024 11:38